<PRE>
[Federal Register: October 25, 2001 (Volume 66, Number 207)]
[Notices]               
[Page 54016-54017]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr25oc01-52]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

 
National Center for Environmental Health; Meeting

    The National Center for Environmental Health (NCEH) of the Centers 
for Disease Control and Prevention (CDC) announces the following 
meeting:

    Name: Applying Genetics and Public Health Strategies to Primary 
Immunodeficiency Diseases.
    Times and Dates:

8 a.m.--6 p.m., November 8, 2001
8 a.m.--1 p.m., November 9, 2001

    Place: Hyatt Regency, 285 Peachtree Street, Atlanta, Georgia 
30309, Phone: 404-577-1234.
    Status: Open to the public for observation and comment, limited 
only by the space available. The meeting room accommodates 
approximately 60 people.
    Purpose: The purpose of the meeting is to identify a public 
health strategy for Primary Immunodeficiency (PI) Disease, including 
a public health assessment, examine laboratory issues including uses 
of genetic tests, to identify public health interventions to 
increase early recognition, to review efforts to increase awareness 
about these diseases among providers and the public, and to identify 
future public health strategies for assessment, intervention, and 
education.
    Matters to be Discussed: The meeting objectives, although 
focused specifically on PI, also establish a framework useful for 
developing public health strategies for other common complex 
diseases. The objectives are: (1) To make a public health assessment 
of primary immunodeficiency diseases; (2) To examine uses of genetic 
tests and role in clinical practice; (3) To identify public health 
interventions to enhance early identification and intervention; (4) 
To review efforts to educate providers, patients and the public 
about primary immunodeficiency; and (5) To identify next steps for 
public health, including research priorities and workshop 
recommendations.
    Agenda items are tentative and subject to change.


CONTACT PERSON FOR MORE INFORMATION: Mary Lou Lindegren, M.D., 
Designated Federal Official, CDC, 4770 Buford Highway, NE, MS K-28, 
Atlanta, Georgia 30341-3724; telephone 770-488-3235, fax 770-488-3236; 
e-mail: <A HREF="mailto:mll3@cdc.gov">mll3@cdc.gov</A>.

[[Page 54017]]

    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining to 
announcements of meetings and other committee management activities for 
both the Centers for Disease Control and Prevention and the Agency for 
Toxic Substances and Disease Registry.

    Dated: October 20, 2001.
John Burckhardt,
Acting Director, Management Analysis and Services Office, Centers for 
Disease Control and Prevention.
[FR Doc. 01-26873 Filed 10-24-01; 8:45 am]
BILLING CODE 4163-18-P

</PRE>